U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H14F4N2O4S
Molecular Weight 430.3751
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BICALUTAMIDE

SMILES

CC(CS(=O)(=O)c1ccc(cc1)F)(C(=Nc2ccc(C#N)c(c2)C(F)(F)F)O)O

InChI

InChIKey=LKJPYSCBVHEWIU-UHFFFAOYSA-N
InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)

HIDE SMILES / InChI

Molecular Formula C18H14F4N2O4S
Molecular Weight 430.3751
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Bicalutamide (brand name Casodex) is an oral non-steroidal anti-androgen for prostate cancer. It is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Bicalutamide competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. When CASODEX is combined with luteinizing hormone releasing hormone (LHRH) analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. Bicalutamide undergoes stereospecific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation. Both the parent and metabolite glucuronides are eliminated in the urine and feces. The S-enantiomer is rapidly cleared relative to the R-enantiomer, with the R-enantiomer accounting for about 99% of total steady-state plasma levels.

CNS Activity

Curator's Comment:: The peripheral selectivity of bicalutamide has been shown to be due to poor penetration across the blood-brain barrier: tissue distribution studies with [3H]bicalutamide show that although it is concentrated in the organs of metabolism and secretion as well as in the prostate, the pituitary glands, and the seminal vesicles, levels in the hypothalamus and the central nervous system (CNS) are much lower than in blood.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CASODEX

Approved Use

Bicalutamide 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Bicalutamide 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies (14.2)

Launch Date

8.1276482E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
810.7 μg/L
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
202.5 μg × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.8 day
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: GONADORELIN
BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
146.4 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: GONADORELIN
BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Other AEs: Gynaecomastia, Breast pain...
Other AEs:
Gynaecomastia (45.2%)
Breast pain (57.1%)
Hot flushes (16.7%)
Constipation (31%)
Dry skin (2.4%)
Insomnia (9.5%)
Rash (11.9%)
Back pain (14.3%)
Asthenia (19%)
Diarrhoea (19%)
Urinary tract infection (16.7%)
Arthralgia (11.9%)
Pharyngitis (14.3%)
Pain (23.8%)
Sources:
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Other AEs: Back pain, Constipation...
Other AEs:
Back pain (6.9%)
Constipation (10.3%)
Libido decreased (50%)
Impotence (57%)
Dyspepsia (6.9%)
Dysuria (6.9%)
Haematuria (6.9%)
Pain (17.2%)
Pelvic pain (6.9%)
Somnolence (6.9%)
Urinary incontinence (6.9%)
Urinary urgency (6.9%)
Weight gain (10.3%)
Gynaecomastia (79%)
Breast tenderness (79%)
Hot flushes (41%)
Sources:
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Other AEs: General body pain, Back pain...
Other AEs:
General body pain (35%)
Back pain (25%)
Asthenia (22%)
Pelvic pain (21%)
Infection (18%)
Abdominal pain (11%)
Chest pain (8%)
Headache (7%)
Flu syndrome (7%)
Hot flashes (53%)
Hypertension (8%)
Constipation (22%)
Nausea (15%)
Diarrhea (12%)
Liver function test increased (7%)
Dyspepsia (7%)
Flatulence (6%)
Anorexia (6%)
Vomiting (6%)
Anemia (11%)
Peripheral edema (13%)
Weight loss (7%)
Hyperglycemia (6%)
Alkaline phosphatase increased (5%)
Weight gain (5%)
Bone pain (9%)
Myasthenia (7%)
Arthritis (5%)
Fracture pathological (4%)
Dizziness (10%)
Paresthesia (8%)
Insomnia (7%)
Anxiety (5%)
Depression (4%)
Dyspnea (13%)
Cough increased (8%)
Pharyngitis (8%)
Bronchitis (6%)
Pneumonia (4%)
Rhinitis (4%)
Rash (9%)
Sweating (6%)
Nocturia (12%)
Hematuria (12%)
Urinary tract infection (9%)
Gynecomastia (9%)
Impotence (7%)
Breast pain (6%)
Urinary frequency (6%)
Urinary retention (5%)
Urination impaired (5%)
Urinary incontinence (4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Arthralgia 11.9%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Rash 11.9%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Back pain 14.3%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Pharyngitis 14.3%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Hot flushes 16.7%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Urinary tract infection 16.7%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Asthenia 19%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Diarrhoea 19%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Dry skin 2.4%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Pain 23.8%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Constipation 31%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Gynaecomastia 45.2%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Breast pain 57.1%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Insomnia 9.5%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
Constipation 10.3%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Weight gain 10.3%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Pain 17.2%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Hot flushes 41%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Libido decreased 50%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Impotence 57%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Back pain 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Dyspepsia 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Dysuria 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Haematuria 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Pelvic pain 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Somnolence 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Urinary incontinence 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Urinary urgency 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Breast tenderness 79%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Gynaecomastia 79%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
Dizziness 10%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Abdominal pain 11%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Anemia 11%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Diarrhea 12%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Hematuria 12%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Nocturia 12%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Dyspnea 13%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Peripheral edema 13%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Nausea 15%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Infection 18%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Pelvic pain 21%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Asthenia 22%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Constipation 22%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Back pain 25%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
General body pain 35%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Depression 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Fracture pathological 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Pneumonia 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Rhinitis 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Urinary incontinence 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Alkaline phosphatase increased 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Anxiety 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Arthritis 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Urinary retention 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Urination impaired 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Weight gain 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Hot flashes 53%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Anorexia 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Breast pain 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Bronchitis 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Flatulence 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Hyperglycemia 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Sweating 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Urinary frequency 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Vomiting 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Dyspepsia 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Flu syndrome 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Headache 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Impotence 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Insomnia 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Liver function test increased 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Myasthenia 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Weight loss 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Chest pain 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Cough increased 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Hypertension 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Paresthesia 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Pharyngitis 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Bone pain 9%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Gynecomastia 9%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Rash 9%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Urinary tract infection 9%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
unlikely (co-administration study)
Comment: this isoenzyme is also responsible for the metabolism of (R)-bicalutamide; (S)-Bicalutamide is metabolised in vitro by CYP3A4
Page: 2.0
low
low
major
minor
minor
no
no
no
no
no
no
no
no
no
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Regulation of GCDFP-15 expression in human mammary cancer cells.
1999 Aug
Rapid and sensitive reporter gene assays for detection of antiandrogenic and estrogenic effects of environmental chemicals.
1999 Mar 1
Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
2001
Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex.
2002 Dec 13
Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.
2003 Dec
Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.
2003 Nov
Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
2004 Aug
Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.
2004 Jun
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
2004 Nov
Secretoglobin 2A1 is under selective androgen control mediated by a peculiar binding site for Sp family transcription factors.
2005 Dec
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
2005 Feb 1
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
2005 Jul 12
Direct agonist/antagonist functions of dehydroepiandrosterone.
2005 Nov
Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
2005 Nov 1
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
2005 Sep 1
The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer.
2006 Apr
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients.
2006 Apr-Jun
Distinct regulation by steroids of messenger RNAs for FSHR and CYP19A1 in bovine granulosa cells.
2006 Aug
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
2006 Jul
GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
2006 Jun 1
DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.
2006 May
Androgen induction of prostate cancer cell invasion is mediated by ezrin.
2006 Oct 6
Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells.
2007 Jan
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
2007 Jul 17
PC-1/PrLZ contributes to malignant progression in prostate cancer.
2007 Sep 15
A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice.
2008 Oct 15
Interactions of methoxyacetic acid with androgen receptor.
2009 Jul 15
Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells.
2011 Apr
Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor.
2013 May 25
Patents

Sample Use Guides

one 50 mg tablet once daily (morning or evening), with or without food
Route of Administration: Oral
Primary tumor cultures and PCa cell lines were treated with bicalutamide (0.1-10 uM) in the presence of dehydrotestosterone (10(-12) M) for 4 days. After bicalutamide treatment, no significant differences in the concentration that inhibits 50% were found among the different tumor cell lines (P = .081).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:59 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:59 UTC 2021
Record UNII
A0Z3NAU9DP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BICALUTAMIDE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
BICALUTAMIDE [HSDB]
Common Name English
ICI176,334-1
Code English
BICALUTAMIDE [ORANGE BOOK]
Common Name English
BICALUTAMIDE [USP]
Common Name English
BICALUTAMIDE [USP-RS]
Common Name English
BICALUTAMIDE [USAN]
Common Name English
ICI-176334
Code English
BICALUTAMIDE [EP MONOGRAPH]
Common Name English
PROPANAMIDE, N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-((4-FLUOROPHENYL)SULFONYL)-2-HYDROXY-2-METHYL-, (+/-)-
Systematic Name English
(+/-)-4'-CYANO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-3-((P-FLUOROPHENYL)SULFONYL)-2-METHYL-M-LACTOTOLUIDIDE
Common Name English
BICALUTAMIDE [USP MONOGRAPH]
Common Name English
BICALUTAMIDE [JAN]
Common Name English
BICALUTAMIDE [INN]
Common Name English
ICI 176,334
Code English
BICALUTAMIDE [MART.]
Common Name English
BICALUTAMIDE [VANDF]
Common Name English
NSC-759816
Code English
BICALUTAMIDE [MI]
Common Name English
CASODEX
Brand Name English
Classification Tree Code System Code
WHO-VATC QL02BB03
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
NDF-RT N0000000243
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
WHO-ATC L02AE51
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
NCI_THESAURUS C146993
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
WHO-ATC L02BB03
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
NDF-RT N0000175560
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
LIVERTOX 105
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
Code System Code Type Description
FDA UNII
A0Z3NAU9DP
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
USP_CATALOG
1071202
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY USP-RS
WIKIPEDIA
BICALUTAMIDE
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
DRUG CENTRAL
367
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
EVMPD
SUB05817MIG
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
PUBCHEM
2375
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
EPA CompTox
90357-06-5
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
IUPHAR
2863
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
MESH
C053541
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
INN
7021
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
NCI_THESAURUS
C1599
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
RXCUI
83008
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY RxNorm
CAS
90357-06-5
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL409
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
HSDB
7655
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
MERCK INDEX
M2474
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB01128
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
Related Record Type Details
ACTIVE ISOMER -> PARENT
INACTIVE ISOMER -> PARENT
Bicalutamide is a racemate and its antiandrogenic activity resides almost exclusively in the (R)-enantiomer, with little, if any, activity in the (S)-enantiomer.
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
TARGET -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BINDER->LIGAND
BINDING
TARGET -> AGONIST
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC